New guidelines on duration of dual antiplatelet therapy in patients with coronary artery disease: what's the novelty?
- PMID: 27867612
- PMCID: PMC5107453
- DOI: 10.21037/jtd.2016.10.98
New guidelines on duration of dual antiplatelet therapy in patients with coronary artery disease: what's the novelty?
Conflict of interest statement
The author has no conflicts of interest to declare.
Comment on
-
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.J Thorac Cardiovasc Surg. 2016 Nov;152(5):1243-1275. doi: 10.1016/j.jtcvs.2016.07.044. J Thorac Cardiovasc Surg. 2016. PMID: 27751237 No abstract available.
References
-
- Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016;68:1082-115. 10.1016/j.jacc.2016.03.513 - DOI - PubMed
-
- Helft G, Steg PG, Le Feuvre C, et al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur Heart J 2016;37:365-74. - PubMed
-
- Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124:e574-651. 10.1161/CIR.0b013e31823ba622 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources